1. Home
  2. DAL vs INSM Comparison

DAL vs INSM Comparison

Compare DAL & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Delta Air Lines Inc.

DAL

Delta Air Lines Inc.

HOLD

Current Price

$68.14

Market Cap

38.2B

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$155.45

Market Cap

35.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAL
INSM
Founded
1924
1988
Country
United States
United States
Employees
78400
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.2B
35.2B
IPO Year
2004
2000

Fundamental Metrics

Financial Performance
Metric
DAL
INSM
Price
$68.14
$155.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
18
23
Target Price
$79.06
$191.09
AVG Volume (30 Days)
7.6M
2.1M
Earning Date
04-14-2026
05-21-2026
Dividend Yield
1.12%
N/A
EPS Growth
43.71
N/A
EPS
7.66
N/A
Revenue
$41,244,000,000.00
N/A
Revenue This Year
N/A
$130.70
Revenue Next Year
$5.64
$74.05
P/E Ratio
$8.73
N/A
Revenue Growth
N/A
N/A
52 Week Low
$34.74
$60.40
52 Week High
$76.39
$212.75

Technical Indicators

Market Signals
Indicator
DAL
INSM
Relative Strength Index (RSI) 47.75 45.50
Support Level $68.50 $139.81
Resistance Level $72.75 $166.84
Average True Range (ATR) 3.03 6.52
MACD -0.42 1.84
Stochastic Oscillator 23.08 45.07

Price Performance

Historical Comparison
DAL
INSM

About DAL Delta Air Lines Inc.

Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke network, where it gathers and distributes passengers across the globe through its biggest hubs in Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta has historically earned most of its international revenue and profits from flying passengers over the Atlantic Ocean.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: